



Date: April 3, 2024

Via Email: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637

To Whom it May Concern:

United Therapeutics Corporation submits this information pursuant to 18 V.S.A. § 4637(b). On April 1, 2024, United Therapeutics Corporation released the following prescription drugs to the commercial market:

NDC	Product Description	WAC
66302-0716-04	TYVASO DPI Institutional Kit- 16mcg x 16	3,288.57
66302-0732-04	TYVASO DPI Institutional Kit- 32mcg x 16	3,288.57
66302-0748-04	TYVASO DPI Institutional Kit- 48mcg x 16	3,288.57
66302-0764-04	TYVASO DPI Institutional Kit- 64mcg x 16	3,288.57

United Therapeutics Corporation provides this notice consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions.

Thank you for your consideration.

Sincerely,

DocuSigned by:

4DC49D1B2FA8476
Felecia Manning

03-Apr-2024 | 11:18:41 AM EDT